Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Regenxbio Inc.

NASDAQ: RGNX · Life Sciences · 4 alerts · CIK 1590877

Share price
$7.32Close, Nov 16
Market cap
$484M
Shares outstanding
66.12MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Regenxbio Inc. filings on SEC EDGAR ↗

7:21 AM ET 10-Q
Financial Results

Regenxbio Q3 2026 Results: Net Loss of $40.7M, Loss Narrows

REGENXBIO Inc. reported total assets of $466.0 million as of September 30, 2026, with a significant increase in cash and cash equivalents to $95.8 million compared to $34.5 million at year-end 2025. The company is currently managing clinical holds on its RGX-121 and RGX-111 programs while continuing development partnerships with AbbVie and Nippon Shinyaku.

Key figure
Net loss $40.7M
7:13 AM ET 8-K
Financial Results

Regenxbio Financial Results

REGENXBIO reported Q3 2026 financial results, highlighting progress toward a BLA submission for its Duchenne muscular dystrophy gene therapy RGX-202 in Q1 2027. The company also expects topline pivotal data for its wet AMD candidate sura-vec in Q4 2026, with global regulatory submissions planned for 2027.

“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028. With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD. We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible. We remain focused on executing these near-term milestones and leveraging our fully integrated capabilities to deliver meaningful new treatment options for patients.”

Curran Simpson, President and Chief Executive Officer of REGENXBIO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.